BDTX
What one share of Black Diamond Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry.
Black Diamond Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.74 |
| Cash and investments | $0.33 |
| Book value | $1.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | $0.00 | −$4.42 | $0.04 | −$4.23 | — | −$7.15 |
| 2019 | $0.00 | −$16.99 | $0.01 | −$11.90 | — | −$21.08 |
| 2020 | $0.00 | −$2.04 | $0.00 | −$1.59 | — | $8.53 |
| 2021 | — | −$3.47 | $0.07 | −$2.84 | — | $5.41 |
| 2022 | — | −$2.51 | $0.01 | −$2.35 | — | $3.18 |
| 2023 | — | −$1.88 | $0.00 | −$1.52 | — | $2.26 |
| 2024 | $0.00 | −$1.27 | $0.00 | −$1.13 | — | $1.47 |
| 2025 | $1.22 | $0.39 | — | $0.51 | — | $1.96 |